New Collaboration with INRA Micalis-MGP will Concentrate on DuPont’s Probiotic Strains and the Understanding of these Microbes’ Mechanism of Action on Human Health.
Building upon the recently announced partnership with TFTAK in March 2018, the DuPont Nutrition & Health Microbiome Venture continues to strengthen its capabilities in announcing the third strategic research and development partnership. The newly forged relationship with INRA (French National Institute for Agricultural Research), through both the Micalis Institute and MetaGenoPolis, a pre-industrial demonstrator, will be focused on deciphering the molecular mechanisms of action of DuPont’s probiotic strains through a functional metagenomics approach.
INRA has developed and validated a high-throughput screening (HTS) platform to test the effect of large DNA fragment in genomic or metagenomic libraries on intestinal epithelial cell lines modified with reporter gene technology. This allows the screening of genomic and metagenomic clones on various reporter systems targeting pathways involved in homeostasis, metabolism, immune control as well as enteroendocrine cell activation.
“We are thrilled to partner with INRA MetaGenoPolis and Micalis Institute as DuPont continues to build its capabilities to lead microbiome innovation through strategic partnerships,” said Microbiome Venture Leader Sebastien Guery. “Following our partnerships with APC Cork to discover new strains for maternal and infant health and with the Center of Food and Fermentation Technologies (TFTAK) in Tallinn, Estonia, to understand the “culturability” of next-generation probiotics, we are nicely complementing our set of capabilities by adding the understanding of the DuPont™ Danisco® probiotics’ mechanisms of action on human health at a molecular level.”
With its world-renowned scientists and excellent technical capabilities in functional genomics, INRA will be a strong partner with DuPont by defining the molecular mechanisms of action of DuPont™ Danisco® probiotic strains. DuPont established the Microbiome Venture to accelerate microbiome science-based solution development through a combination of selected strategic partnerships with microbiome science leaders and internal investments.
INRA, through its Micalis Institute and metagenomics platforms at MetaGenoPolis, collaborates with many leaders in the field, worldwide, contributing its know-how and tools to discoveries and breakthrough of high impact. INRA is the major European actor in the field of gut microbiota in terms of publications.
DuPont has a long-standing innovation relationship with INRA that began as early as 1987 when DuPont was the first company to sponsor INRA Ph.D. theses. Building on this fruitful collaboration, this new partnership will be part of the Qualiment® network, which has been awarded the "Carnot Institute" label of excellence. Qualiment® is a network of research institutes and universities created to provide the necessary scientific and technological resources to support companies in developing new food products with higher sensory and nutritional qualities and for a sustainable alimentation.
Established in late 2017, the Microbiome Venture is an entrepreneurial team drawing on DuPont capabilities, including R&D, manufacturing, regulatory, legal and marketing. The Microbiome Venture investment will complement DuPont’s existing product portfolio, especially in the areas of probiotics and prebiotics, including human milk oligosaccharides (HMOs.)
To find out more or to contact us, please go to HMV
INRA, L’INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, a French Governmentalresearch Institution, is the No. 1 European agricultural research institute and No. 2 for agricultural science in the world. It has the mission to contribute, through the development of skills, know-how and research results, to the design of technological and social innovations, as well as to organize free access to scientific data and publications in accordance with French and European rules on opening public data and free access to scientific publications. INRA has combined, more than 10 years ago, its efforts in nutrition, microbiology and genomics by developing its research in gut microbiota through metagenomics approaches. To find out more about us, please visit www.micalis.fr and www.mgps.eu
DuPont Nutrition & Health, a DowDuPont Specialty Products Division business, combines in-depth knowledge of food and nutrition with current research and expert science to deliver unmatched value to the food, beverage, pharmaceutical and dietary supplement industries. We are innovative solvers, drawing on deep consumer insights and a broad product portfolio to help our customers turn challenges into high-value business opportunities. More information is available at www.food.dupont.com
DowDuPont Specialty Products, a division of DowDuPont (NYSE: DWDP), is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, building and construction, health and wellness, food and worker safety. DowDuPont intends to separate the Specialty Products Division into an independent, publicly traded company. More information can be found www.dow-dupont.com